Drug Resistance Could Kill 10M People per year by 2050, Experts say (Axios).
Infectious disease experts tell Axios they agree with a dire scenario painted in the UN report posted earlier this week saying that, if nothing...
CDC’s Worst-Case Coronavirus Model: 214 Million Infected, 1.7 Million Dead (Intelligencer)
A recent CDC projection estimated that the U.S. coronavirus epidemic could infect between 160 million and 214 million people over a period...
‘Amazing potential.’ UM doctor to start stem cell trial for coronavirus patients (Miami Herald)
BY BEN CONARCK APRIL 16, 2020
A team of doctors at the University of Miami won emergency federal approval...
American BriVision (ABVC) Improves Working Capital and Reduce Debt.
American BriVision Announces Two Financial Transactions to Improve Working Capital and Reduce Debt
FREMONT, CA, April 13, 2020...
FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!
FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome.
Qiming Venture Partners Raises $1.1 Billion Fund VII
Qiming USA Portfolio
The vast majority of Qiming's capital comes from a prestigious group of endowments, foundations, family offices,...
Exosomes, Extracellular Vesicles, and the CoronaVirus.
Uploading a Series of Articles on Extracellular Vesicles, Including Potential Effects on the CoronaVirus and ARDS.
Article #1:...
Adding Corbis Pharma (CRBP) $5.55 to Watch List.
Running Clinical Trials Full Steam With $46 Million Banked in Late February.
Not thinly, but lightly traded. Ready,...
Boo Ya. Brokerage Sets $12 Price Target for Athersys (ATHX) $2.96.
A major Wall Street firm that specializes in Bio and Medtech Companies has a $12 price target out on Athersys from one...
Adding Organicell (BPSR) $0.02 to the Watch List.
Organicell (BBSR). New client, studying now. Thinly, thinly traded and expectedly volatile on an intra-day basis. Like what we’ve read so far...
Latest article
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.
Can You Imagine Selling Solgenix at $2.00 yesterday.
And to be honest, news wasn't all that big - such...
